Core Viewpoint - Kangnibei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kangnibei Pharmaceutical Co., Ltd. to market a 0.25g specification of Tranexamic Acid Tablets [1] Group 1 - The original manufacturer of Tranexamic Acid Tablets is Daiichi Sankyo Co., Ltd. from Japan, which has approved both 0.25g and 0.5g specifications in Japan, with the 0.5g specification already approved for sale in China [1] - Tranexamic Acid Tablets are primarily used for treating various bleeding conditions caused by acute or chronic, localized or systemic primary fibrinolysis, as well as secondary hyperfibrinolytic states due to disseminated intravascular coagulation [1]

氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有0.25g规格和0.5g规 格，其中0.5g规格在中国获批上市。氨甲环酸片主要用于急性或慢性、局限性或全身性原发性纤维蛋白 溶解亢进所致的各种出血;弥散性血管内凝血所致的继发性高纤溶状态。 智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司("杭州 康恩贝")收到国家药品监督管理局(以下简称"国家药监局")核准签发的规格为0.25g的氨甲环酸片《药品 注册证书》。 ...

Core Viewpoint - 康恩贝's subsidiary, Hangzhou Kang En Bei, has received approval from the National Medical Products Administration for the drug Aminocaproic Acid Tablets, which is expected to positively impact the company's performance [1] Group 1: Drug Approval Details - The approved drug is specified as 0.25g Aminocaproic Acid Tablets, primarily used for various bleeding conditions caused by primary fibrinolysis and secondary hyperfibrinolysis due to disseminated intravascular coagulation [1] - The registration application was submitted in April 2024 and has now been approved, indicating a successful regulatory process [1] Group 2: Financial Implications - Hangzhou Kang En Bei has invested approximately 6.27 million yuan in research and development for this drug [1] - The drug is considered to have passed the consistency evaluation for generic drugs according to national policies, which is expected to have a positive impact on the company's financial performance [1]

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kang En Bei Pharmaceutical Co., Ltd. to market Tranexamic Acid Tablets, which are primarily used for various bleeding conditions caused by hyperfibrinolysis [1] Group 1 - The approved specification for Tranexamic Acid Tablets is 0.25g [1] - The drug is indicated for both acute and chronic bleeding, whether localized or systemic, due to primary hyperfibrinolysis [1] - It is also used for secondary hyperfibrinolytic states caused by disseminated intravascular coagulation [1]

证券简称：康恩贝 证券代码：600572 编号：2025-037 浙江康恩贝制药股份有限公司 关于子公司培哚普利氨氯地平片（Ⅲ） 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20254915 证书编号：2025S02246 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的培哚普利氨氯地平片（Ⅲ）《药品注册证书》，现将相关情 况公告如下： 一、药品注册证书的主要内容 药品名称：培哚普利氨氯地平片（Ⅲ） 剂型：片剂 规格：每片含精氨酸培哚普利 10mg、苯磺酸氨氯地平 5mg（按 C₂₀H₂₅N₂O₅Cl 计） 三、其他相关情况 根据国家药监局网站显示，截至本公告日，培哚普利 ...

Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-036 浙江康恩贝制药股份有限公司 关于注销回购股份实施结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、回购审批情况和回购方案内容 2024 年 1 月 22 日，浙江康恩贝制药股份有限公司(以下简称"公司")召开第十 届董事会第三十七次（临时）会议，审议通过《关于以集中竞价交易方式回购公司 股份的议案》，并于 2024 年 1 月 23 日在《中国证券报》《上海证券报》《证券时报》 和上海证券交易所网站 www.sse.com.cn（指定信息披露媒体和披露网址下同）披露 了临 2024—006 号《公司关于以集中竞价交易方式回购股份方案的公告》。2024 年 1 月 27 日，公司披露了临 2024—008 号《公司关于以集中竞价交易方式回购股份的回 购报告书》。本次股份回购方案的主要内容如下：同意公司使用自有资金通过上海证 券交易所以集中竞价交易方式回购公司股份，用于实施股权激励。拟回购股份的资 金总额不低于 20,000 万元（含） ...

Core Points - The company announced the results of the stock option incentive plan for the second quarter of 2025, with a total of 492,437 shares exercised [1][8] - The stock option plan was initially approved in September 2022, allowing for the grant of 70 million stock options [1][2] - The exercise price of the stock options was adjusted multiple times, with the latest adjustment setting it at 3.78 yuan per share for the initial grant and 5.07 yuan for reserved options [3][4][5] Summary by Sections Incentive Plan Overview - The stock option incentive plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange [1][2] - The plan allows for the grant of stock options to 537 individuals, with a total of 62.475 million options registered [1][2] Adjustments to Exercise Price - The exercise price was adjusted from 4.13 yuan to 3.98 yuan in June 2023 following a cash dividend distribution [2][3] - Further adjustments were made in July 2024, reducing the exercise price to 3.78 yuan for initial options and 5.07 yuan for reserved options [4][5] Exercise Results - As of the second quarter of 2025, a total of 1,486,712.7 shares were exercised, with the total number of shares exercised reaching 49,243.7 shares [6][7] - The shares obtained through the exercise will be tradable two trading days after the exercise date [7] Impact on Share Capital Structure - The total number of shares increased from 2,584,412,009 to 2,584,904,446 after the exercise, with the distribution of shares remaining compliant with listing requirements [7][8] - The company raised 1.844387 million yuan from the exercise of stock options [7]

2025年第二季度，公司本次激励计划激励对象行权且完成股份过户登记的股票 数量合计为49.2437万股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会 第十三次（临时）会议分别审议通过了《关于<浙江康恩贝制药股份有限公司2022年 股票期权激励计划（草案）>及摘要的议案》及其他相关议案，公司独立董事、监事 会 、 律师 均 发 表 了相 关 意 见 ，并 于 2022 年9 月 16 日 在 上海 证 券交 易 所 网 站 www.sse.com.cn和《中国证券报》《上海证券报》《证券时报》（以下统称：公司 指定信息披露媒体）进行了详尽披露。（公告编号：临2022-046、临2022-047、临 2022-048） 证券代码：600572 证券简称：康恩贝 公告编号：临2025-035 浙江康恩贝制药股份有限公司 关于2025年第二季度股票期权激励计划 2、本次行权股票上市流通时间：采用自主行权方式行权，激励对象（除公司董事、高级管 理人员外）行权所得股票于行权日（T 日）后的第二个交易日（T+2）日可上市交易 ...

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]